Radiation-Induced Myelosuppression Treatment Market 2018 to 2028 By Top Players | Amgen Inc., Janssen Pharmaceutical NV, Teva Pharmaceutical Industries Ltd., Mylan NV, Novartis AG

Top 3 Leading Manufacturers Account for Majority of the Revenue of the Radiation-Induced Myelosuppression Treatment Market

The radiation-induced myelosuppression treatment market is dominated by the top 3 manufacturers, i.e., Amgen Inc., Janssen Pharmaceutical NV and Teva Pharmaceutical Industries Ltd., who are competing on the basis of new drug approvals and geographical presence. The manufacturers of radiation-induced myelosuppression treatment are focusing on the expansion of their product portfolios by launching different products in various regions.

Amgen Inc. holds a significant revenue share in the global radiation-induced myelosuppression treatment market. Amgen Inc. also holds patents for various formulations, and is recently facing high competition from the new biosimilars that have been introduced in the radiation-induced myelosuppression treatment market from other manufacturers such as Teva Pharmaceutical Industries Ltd., Janssen Pharmaceutical NV, Sandoz, Pfizer Inc., Mylan NV and others. Through collaborations and partnerships with regional players, the manufacturers of radiation-induced myelosuppression treatment market are focusing on expanding their regional product footprint by launching new and innovative products.

Get Sample Copy of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8116

Rapidly Increasing Incidence of Cancer and Decreasing Mortality Rate is Expected to Fuel Growth of the Radiation-Induced Myelosuppression Treatment Market

Although the incidence of cancer is increasing rapidly, the death rate due to cancer has decreased from 1991 to 2015, which is, in turn, contributing to revenue generation in the radiation-induced myelosuppression treatment market. According to SEER Cancer statistics, the overall death rate due to cancer in the U.S. fell by 26.0% during 1991 – 2015, which can be majorly attributed to early diagnosis and the availability of advanced treatment options such as radiotherapy, chemotherapy & surgical procedures. The early diagnosis of cancer has boosted the treatment-seeking rate in developed countries, which is a major driver of the radiation-induced myelosuppression treatment market. The radiation-induced myelosuppression treatment also holds significant potential for revenue generation in developing countries owing to improved healthcare infrastructure.

Patent Expiry of Various Originator Formulations in the Radiation-Induced Myelosuppression Treatment Market

The expiry of the patents of various biologics formulations in the radiation-induced myelosuppression treatment market provides opportunities for other manufacturers in the radiation-induced myelosuppression treatment market to launch biosimilars. Majority of the patents in the radiation-induced myelosuppression treatment market were held by Amgen Inc. However, they have expired in the past five years, i.e. from 2013 to 2018, which has subsequently led to the launch and approval of various biosimilars in the high revenue-generating markets such as North America and Europe. For example, the patent for Amegen Inc.’s Neulasta, a biologic used for the treatment of neutropenia, expired in 2015 in the U.S., following which Sandoz launched Zarxio, the first biosimilar in the U.S. Although the cost variation between originator formulations and biosimilars is only 15% to 20%, it can reduce the economic burden on patients. This is driving the radiation-induced myelosuppression treatment market due to the increasing adoption of biosimilars in radiation-induced myelosuppression treatment.

Improved Efficacy with Iron Therapy along with Erythropoietin-Stimulating Agents is Positively Impacting the Radiation-Induced Myelosuppression Treatment Market

The need for blood transfusion is high in radiation-induced anemia as compared to chemotherapy-induced anemia, due to which erythropoietin-stimulating agents are used alone for radiation-induced myelosuppression treatment. Whereas, the usage of iron therapy along with Erythropoietin-Stimulating Agents (ESA) in radiation-induced myelosuppression treatment significantly lowers the need for blood transfusion. The IV iron therapy coupled with ESA helps bring the RBC count back to the normal level as compared to treatment with ESA alone. As per a study carried out by Auerbach et al., the response rate of ESA alone was 62–73% after being used for 2 to 3 weeks, whereas the response rate for treatment with ESA coupled with iron therapy was 77–86%. This significant change in the response rate will help improve efficacy and therapeutic outcomes as well as patient compliance, thus generating higher revenue in the radiation-induced myelosuppression treatment market.

Competitive Landscape

This section of the report features the profiles of the key players operating in the radiation-induced myelosuppression treatment market based on their market shares, differential strategies, product offerings, marketing approach and company dashboard. Examples of some of the key players featured in this report include Amgen Inc., Janssen Pharmaceutical NV, Teva Pharmaceutical Industries Ltd., Mylan NV, Novartis AG, Pfizer Inc., Janssen Global Services, LLC (Johnson & Johnson), Partner Therapeutics, Inc. and others.

The key manufacturers of radiation-induced myelosuppression treatment are focusing on increasing their geographical footprints as well as launching products to increase their revenue generation in the radiation-induced myelosuppression treatment market.

Definition

Radiation-induced myelosuppression is defined as the decreased ability of the bone marrow to produce blood cells (WBC, RBC and platelets). It occurs most commonly with cancer as an adverse effect of radiation, especially in case of cancers that are located near the bone marrow or near large bones with cavities. Radiation-induced myelosuppression can result in the decreased production of red blood cells (anaemia), white blood cells (leukopenia) and platelets (thrombocytopenia).

About the Report

The company conducted a research study on the radiation-induced myelosuppression treatment market for the forecast period 2018 to 2028. The report offers a comprehensive evaluation of the business opportunities prevailing in the radiation-induced myelosuppression treatment market with insights on the prices, current trends and reimbursement scenario in the radiation-induced myelosuppression treatment market.

Segmentation

The report offers a comprehensive taxonomy of the radiation-induced myelosuppression treatment market based on the indication, drug class, route of administration, distribution channel and region. By indication, the radiation-induced myelosuppression treatment market is segmented into neutropenia, anaemia and thrombocytopenia. By drug class, the radiation-induced myelosuppression treatment market is segmented into growth factors, erythropoietin stimulating agents, thrombopoietic agents, iron supplements and others. By route of administration, the radiation-induced myelosuppression treatment market is segmented as oral and injectable. By distribution channel, the radiation-induced myelosuppression treatment market is segmented into hospitals pharmacies, retail pharmacies, online pharmacies and drug stores. The radiation-induced myelosuppression treatment market has been analysed across the regions of North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan, Japan and the Middle East & Africa (MEA).

Additional Questions Answered

Some of the additional questions addressed in this report on the radiation-induced myelosuppression treatment market:

What is the revenue generation potential of the radiation-induced myelosuppression treatment market across the regions of North America and Europe?

Who are the key competitors and what are their portfolios in the radiation-induced myelosuppression treatment market?

What are major challenges influencing the growth of the radiation-induced myelosuppression treatment market?

Request Customized Copy of Report @ https://www.futuremarketinsights.com/customization-available/rep-gb-8116

Research Methodology

The radiation-induced myelosuppression treatment market has been estimated based on a supply-demand approach. The market was first calculated based on the epidemiology of myelosuppression in different regions/countries in radiation-induced myelosuppression treatment. Some of the other qualitative factors analysed include the awareness level and the availability of drugs for radiation-induced myelosuppression treatment for different indications. This information is further validated with rigorous primary research (which includes interviews, surveys, in-person interactions and the viewpoints of seasoned analysts) and secondary research (which includes verified paid sources, authentic trade journals and resourceful databases). The research study on the radiation-induced myelosuppression treatment market also includes the top trends and the macro- as well as micro-economic factors shaping the radiation-induced myelosuppression treatment market. With this approach, the report on the radiation-induced myelosuppression treatment market estimates the industry attractiveness of every major segment in the radiation-induced myelosuppression treatment over the forecast period.

About Us

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Contact Us

U.S. Office

616 Corporate Way, Suite 2-9018,

Valley Cottage, NY 10989,

United States

T: +1-347-918-3531

F: +1-845-579-5705

Email: sales@futuremarketinsights.com

Web: https://www.futuremarketinsights.com/

This release was published on openPR.